The frequency of missed breast cancers in women participating in a high-risk MRI screening program

AbstractPurposeTo evaluate the frequency of missed cancers on breast MRI in women participating in a high-risk screening program.MethodsPatient files from women who participated in an increased risk mammography and MRI screening program (2003 –2014) were coupled to the Dutch National Cancer Registry. For each cancer detected, we determined whether an MRI scan was available (0–24 months before cancer detection), which was reported to be negative. These negative MRI scans were in consensus re-evaluated by two dedicated breast radiolog ists, with knowledge of the cancer location. Cancers were scored as invisible, minimal sign, or visible. Additionally, BI-RADS scores, background parenchymal enhancement, and image quality (IQ; perfect, sufficient, bad) were determined. Results were stratified by detection mode (mammography, MRI, in terval cancers, or cancers in prophylactic mastectomies) and patient characteristics (presence ofBRCA mutation, age, menopausal state).ResultsNegative prior MRI scans were available for 131 breast cancers. Overall 31% of cancers were visible at the initially negative MRI scan and 34% of cancers showed a minimal sign. The presence of aBRCA mutation strongly reduced the likelihood of visible findings in the last negative MRI (19 vs. 46%,P 
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research

Related Links:

A urinary incontinence drug is surprisingly effective in the treatment of hot flashes for both women with a history of breast cancer and those with menopausal symptoms but who do not have cancer.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
FRIDAY, Dec. 7, 2018 -- Hot flashes, a common curse in menopause, can be especially bothersome after breast cancer. But a new study suggests an existing medication may help. The drug is oxybutynin (Ditropan XL), long used to treat urinary...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
FRIDAY, Dec. 7, 2018 -- Hot flashes, a common curse in menopause, can be especially bothersome after breast cancer. But a new study suggests an existing medication may help. The drug is oxybutynin (Ditropan XL), long used to treat urinary...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
FRIDAY, Dec. 7, 2018 -- Hot flashes, a common curse in menopause, can be especially bothersome after breast cancer. But a new study suggests an existing medication may help. The drug is oxybutynin (Ditropan XL), long used to treat urinary...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Older women with excess body fat, even if they have what's considered a normal body-mass index, could be at greater risk for breast cancer, according to a study published Thursday in the medical journal JAMA Oncology.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
This article, however, is more of a commentary on high level strategy and the effects of regulation, coupled with a desire to forge ahead rather than hold back in the matter of treating aging, thus I concur with much more of what is said than is usually the case. For decades, one of the most debated questions in gerontology was whether aging is a disease or the norm. At present, excellent reasoning suggests aging should be defined as a disease - indeed, aging has been referred to as "normal disease." Aging is the sum of all age-related diseases and this sum is the best biomarker of aging. Aging and its d...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
AbstractLetrozole is an aromatase inhibitor, used to treat post ‐menopausal women with hormone receptor‐positive or unknown advanced breast cancer. It is prohibited in sport because it is used together with androgen anabolizing steroids to avoid their adverse effects. In case of adverse analytical finding, it may be important to distinguish between repetitiv e use due to voluntary administration and occasional use, possibly due to involuntary intake. With the objective to identify the dose capable of producing a positive hair testing, and to apply these results to the scenarios of letrozole inadvertent ingestion by an ...
Source: Drug Testing and Analysis - Category: Drugs & Pharmacology Authors: Tags: RESEARCH ARTICLE Source Type: research
Conclusion: Postmenopausal women with invasive breast cancer experience a significantly shorter survival than do their premenopausal counterparts. The predictors of worse overall survival were molecular subtype, stage of disease and type of treatment administered. PMID: 30486605 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Authors: Alexiades M Abstract Genitourinary syndrome of menopause (GSM), encompassing the disorders of atrophic vaginitis, urinary incontinence, and pelvic prolapse, affects the majority of postmenopausal women, as well as patients who are undergoing breast cancer treatement, post-ovarectomy, post-radiation, and breast-feeding. There is a need for better treatment options for these common conditions that adversely affect physical function and quality of life and that are often underserved by existing options. Lasers have been used to treat genitourinary tissue for over 40 years, and over the past decade, several la...
Source: Seminars in Cutaneous Medicine and Surgery - Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
Hyperprolactinemia is not a common finding in postmenopausal women. Prolactinomas detected after menopause are usually macroadenomas. Due to atypical clinical features they may remain unrecognized for a long period of time. Interestingly the growth potential of prolactinomas remains after menopause. Most tumors are invasive and present with high prolactin levels. They respond to medical treatment with dopamine agonists in terms of prolactin normalization, tumor shrinkage, and improvement in pituitary function. Treatment with dopamine agonists is usually long term. Reducing doses of cabergoline to the lowest that keeps prol...
Source: Neuroendocrinology - Category: Endocrinology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Mammography | Mastectomy | Men | Menopause | Netherlands Health | PET Scan | Study | Women